Another HER2 selective inhibitor, Tukysa (tucatinib) was approved in 2020 in combination with trastuzumab and capecitabine for patients with metastatic unresectable or advanced HER2 breast cancer with brain metastases who had received prior anti-HER2 therapy. Here, ERBB2 is linked to breast cancer.